PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients

Authors :: Graaf, W.T.A. van der
Blay, J.Y.
Chawla, S.P.
Kim, D.W.
Nguyen, B.B.
Casali, P.G.
Schoffski, P.
Aglietta, M.
Staddon, A.P.
Beppu, Y.
Cesne, A. le
Gelderblom, H.
Judson, I.R.
Araki, N.
Ouali, M.
Marreaud, S.
Hodge, R.
Dewji, M.
Tos, A.P. dei
Hohenberger, P.
Source :: Journal of Clinical Oncology, 30(15)
Publication Year :: 2012

Tools